{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Epivir+%283TC%29&page=2", "query": { "intervention": "Epivir (3TC)", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 311, "total_pages": 32, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Epivir+%283TC%29&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Epivir+%283TC%29&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-30T08:07:20.711Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00051038", "title": "Study of Adding Entecavir to Current Lamivudine Therapy in HIV and HBV Co-Infected Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Hepatitis B" ], "interventions": [ { "name": "Entecavir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": null, "start_date": "2002-09", "completion_date": "2005-10", "has_results": false, "last_update_posted_date": "2011-04-14", "last_synced_at": "2026-09-30T08:07:20.711Z", "location_count": 5, "location_summary": "New Haven, Connecticut • Altamonte Springs, Florida • Lousiville, Kentucky + 2 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Altamonte Springs", "state": "Florida" }, { "city": "Lousiville", "state": "Kentucky" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00051038" }, { "nct_id": "NCT02120352", "title": "A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Infection, Human Immunodeficiency Virus", "HIV Infections" ], "interventions": [ { "name": "CAB Oral Tablets", "type": "DRUG" }, { "name": "CAB LA", "type": "DRUG" }, { "name": "ABC/3TC Oral tablets", "type": "DRUG" }, { "name": "RPV Oral Tablets", "type": "DRUG" }, { "name": "HAART", "type": "OTHER" }, { "name": "RPV", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 309, "start_date": "2014-04-28", "completion_date": "2023-04-20", "has_results": true, "last_update_posted_date": "2024-06-12", "last_synced_at": "2026-09-30T08:07:20.711Z", "location_count": 15, "location_summary": "Birmingham, Alabama • Bakersfield, California • Beverly Hills, California + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Bakersfield", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02120352" }, { "nct_id": "NCT00002424", "title": "A Study to Compare the Safety and Effectiveness of Indinavir Combined With Stavudine and Lamivudine", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "L-756423", "type": "DRUG" }, { "name": "Indinavir sulfate", "type": "DRUG" }, { "name": "Lamivudine", "type": "DRUG" }, { "name": "Stavudine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 186, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-09-30T08:07:20.711Z", "location_count": 16, "location_summary": "Los Angeles, California • Washington D.C., District of Columbia • Fort Myers, Florida + 9 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002424" }, { "nct_id": "NCT00002397", "title": "A Study of Saquinavir Soft Gel Capsules (SGC) Used in Combination With Two Other Anti-HIV Drugs in Patients With HIV-Associated Kidney Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV Infections", "AIDS-Associated Nephropathy" ], "interventions": [ { "name": "Nelfinavir mesylate", "type": "DRUG" }, { "name": "Saquinavir", "type": "DRUG" }, { "name": "Lamivudine", "type": "DRUG" }, { "name": "Stavudine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-09-30T08:07:20.711Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002397" }, { "nct_id": "NCT00002368", "title": "The Safety and Effectiveness of Nevirapine Plus Lamivudine Plus Other Anti-HIV Drugs", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Nevirapine", "type": "DRUG" }, { "name": "Lamivudine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": null, "sex": "ALL", "summary": "13 Years and older" }, "enrollment_count": 2000, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-09-30T08:07:20.711Z", "location_count": 53, "location_summary": "Montgomery, Alabama • Los Angeles, California • Palo Alto, California + 41 more", "locations": [ { "city": "Montgomery", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Redwood City", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002368" }, { "nct_id": "NCT00002245", "title": "A Study of the Effects of Amprenavir, a Protease Inhibitor, on Carbohydrate and Fat Metabolism in HIV-Infected Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Abacavir sulfate", "type": "DRUG" }, { "name": "Amprenavir", "type": "DRUG" }, { "name": "Lamivudine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Glaxo Wellcome", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "1999-04", "completion_date": null, "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-09-30T08:07:20.711Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002245" }, { "nct_id": "NCT07001319", "title": "Study of GS-3242 in Participants With HIV-1; Substudy-05", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV-1-infection" ], "interventions": [ { "name": "GS-3242", "type": "DRUG" }, { "name": "BVY", "type": "DRUG" }, { "name": "Standard of Care", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 27, "start_date": "2025-05-29", "completion_date": "2026-04-16", "has_results": false, "last_update_posted_date": "2026-05-11", "last_synced_at": "2026-09-30T08:07:20.711Z", "location_count": 21, "location_summary": "Bakersfield, California • Los Angeles, California • San Francisco, California + 15 more", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07001319" }, { "nct_id": "NCT01102972", "title": "A Simplification Study of Unboosted Reyataz With Epzicom (ASSURE)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Infection, Human Immunodeficiency Virus" ], "interventions": [ { "name": "Reyataz + Norvir + Truvada", "type": "DRUG" }, { "name": "Reyataz + Epzicom", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 297, "start_date": "2010-04", "completion_date": "2012-12", "has_results": true, "last_update_posted_date": "2013-11-19", "last_synced_at": "2026-09-30T08:07:20.711Z", "location_count": 44, "location_summary": "Hobson City, Alabama • Phoenix, Arizona • Bakersfield, California + 36 more", "locations": [ { "city": "Hobson City", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Beverly Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01102972" }, { "nct_id": "NCT05911360", "title": "A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAF", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV", "HIV Infections" ], "interventions": [ { "name": "DTG/3TC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 205, "start_date": "2023-07-07", "completion_date": "2026-02-09", "has_results": true, "last_update_posted_date": "2026-07-09", "last_synced_at": "2026-09-30T08:07:20.711Z", "location_count": 24, "location_summary": "Phoenix, Arizona • Bakersfield, California • Palm Springs, California + 21 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Palm Springs", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Ft. Pierce", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05911360" }, { "nct_id": "NCT00380159", "title": "Open-Label, 48-Week Extension Study of Elvucitabine in Combination With Background Antiretroviral Therapy (ART) for Participants Who Have Completed Study ACH443-014A", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Human Immunodeficiency Virus (HIV)-1 Infection" ], "interventions": [ { "name": "Elvucitabine", "type": "DRUG" }, { "name": "Lamivudine", "type": "DRUG" }, { "name": "Emtricitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alexion Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 4, "start_date": "2006-09", "completion_date": "2009-01", "has_results": false, "last_update_posted_date": "2023-08-14", "last_synced_at": "2026-09-30T08:07:20.711Z", "location_count": 2, "location_summary": "Atlanta, Georgia • Cincinnati, Ohio", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00380159" } ] }